Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Share-based Compensation (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Share-based Compensation for 13 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 56.39% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.0 million through Dec 2025, down 38.98% year-over-year, with the annual reading at $17.0 million for FY2025, 38.98% down from the prior year.
  • Share-based Compensation hit $2.8 million in Q4 2025 for Coherus Oncology, down from $3.4 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $12.9 million in Q1 2022 to a low of $800000.0 in Q1 2021.
  • Historically, Share-based Compensation has averaged $7.7 million across 5 years, with a median of $7.3 million in 2024.
  • Biggest YoY gain for Share-based Compensation was 6488.07% in 2021; the steepest drop was 91.63% in 2021.
  • Year by year, Share-based Compensation stood at $10.9 million in 2021, then rose by 7.13% to $11.7 million in 2022, then dropped by 7.91% to $10.8 million in 2023, then tumbled by 40.88% to $6.4 million in 2024, then plummeted by 56.39% to $2.8 million in 2025.
  • Business Quant data shows Share-based Compensation for CHRS at $2.8 million in Q4 2025, $3.4 million in Q3 2025, and $5.4 million in Q2 2025.